Discover

PHAT
Phathom Pharmaceuticals, Inc.
11.63
2 x 11.58
3 x 11.61
bid
ask
+
0.38
3.38%
12:04 PM
timesize
Ytd-29.90%
1y47.22%
11.12
day range
11.62
7.61
52 week range
18.31
Open11.16Prev Close11.25Low11.12High11.62Mkt Cap897.25M
Vol427.15KAvg Vol1.23MEPS-1.47P/E-7.65Forward P/E7.60
Beta0.49Short Ratio9.36Inst. Own83.10%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning04-3050-d Avg10.98200-d Avg12.691yr Est23.70

PHAT News

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
globenewswire.com
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update

Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT Management to host con

benzinga.com
Phathom Pharmaceuticals Completes Patient Enrollment In Its Phase 2 pHalcon-EoE-201 Clinical Study O

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and c

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
globenewswire.com
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 St

This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Confere

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Confere

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
globenewswire.com
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease W

FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
globenewswire.com
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
seekingalpha.com
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.18 per share versus the Za

Earnings Scheduled For April 30, 2026
benzinga.com
Earnings Scheduled For April 30, 2026

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

FLORHAM PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),

12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
globenewswire.com
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update o

Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., A

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of “Moderate Buy” from Analysts
defenseworld.net
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of “Moderate Buy” from Analyst

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report) has received a consensus recommendati

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),

Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target
247wallst.com
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target

Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Eq

This Argan Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
benzinga.com
This Argan Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday

Top Wall Street analysts upgraded PHAT and PWR, while AGX was upgraded to Overweight with a $550 pri

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.25 Consensus PT from Brokerages
defenseworld.net
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.25 Consensus PT from Brokerages

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report) has earned a consensus recommendation

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
seekingalpha.com
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference T

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference T

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
seekingalpha.com
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates
zacks.com
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.08 per share versus the Za

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
globenewswire.com
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 202

Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175

Earnings Scheduled For February 26, 2026
benzinga.com
Earnings Scheduled For February 26, 2026

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
globenewswire.com
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Bu

FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),

Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
benzinga.com
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's

12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

Earnings Scheduled For October 30, 2025
benzinga.com
Earnings Scheduled For October 30, 2025

benzinga.com
Earnings Scheduled For August 7, 2025

benzinga.com
Earnings Scheduled For May 1, 2025

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  During Monday's trading, 1214 companies set new 52-week lows.